Emerging options in the treatment of bipolar disorders.
Bipolar disorder is a common and severe condition, and has a clinical outcome that is frequently sub-optimal. Only a small number of therapeutic options are currently available for the disorder. A growing range of novel therapeutic options for the treatment of bipolar disorder are under investigation. These include the anticonvulsants, atypical antipsychotics and options such as the omega-3 fatty acids and transcranial magnetic stimulation. Of the anticonvulsants, lamotrigine is currently the agent for which the greatest amount of controlled clinical data is accumulating, particularly in the depressed and rapid cycling phases of the illness. Olanzapine is currently the atypical antipsychotic with the largest body of evidence in mania, although data is emerging on other atypical antipsychotics including risperidone and ziprasidone. Data regarding the atypical agents in other phases of the illness are awaited. The options available for this difficult to treat condition is increasing with the new range of agents.
Berk
M
M
Department of Psychiatry, University of Melbourne, Geelong, Victoria, Australia. mikebe@barwonhealth.org.au
Segal
J
J
Janet
L
L
Vorster
M
M
D000927:Anticonvulsants / Q000494:pharmacology / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004599:Electric Stimulation Therapy; D004565:Electroconvulsive Therapy; D015525:Fatty Acids, Omega-3 / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008280:Magnetics; D011379:Prognosis; D012886:Skull
D000927:Anticonvulsants; D014150:Antipsychotic Agents; D015525:Fatty Acids, Omega-3